Company intelligence

Moonwalk Biosciences

Last verified Sep 8, 2026

Key Metrics

Total funding
~$127M
As of Sep 8, 2026BioSpace

Recent changes

  1. Sep 8, 2026Raised $70M Series B BioSpace
  2. Sep 8, 2026First reported total funding: ~$127M BioSpace
  3. Sep 8, 2026New investor: Eli Lilly and Company BioSpace
  4. Sep 8, 2026New investor: ARCH Venture Partners BioSpace
  5. Sep 8, 2026New investor: Future Ventures BioSpace
Earlier changes (3)
  1. Sep 8, 2026New investor: Alpha Wave Global BioSpace
  2. Sep 8, 2026New investor: Khosla Ventures BioSpace
  3. Sep 8, 2026Moonwalk Biosciences Raises $70M For Obesity RNAi Pulse story

Funding History

1 event · sources dated per row
DateEventAmountValuationInvestorsSource
Sep 8, 2026Series B$70M—BioSpace

Investors

Latest Pulse

  1. Moonwalk Biosciences Raises $70M For Obesity RNAiMoonwalk Biosciences closed an oversubscribed $70 million Series B to advance an adipose-targeted RNA interference therapy for obesity toward its first human trial, bringing total funding to roughly $127 million since its 2024 launch.→

Coverage Timeline

newest first
  1. Sep 8, 2026FUNDINGMoonwalk Biosciences Raises $70M For Obesity RNAi$70M Series B→

All Coverage

Related Companies

Moonwalk Biosciences FAQ

How much has Moonwalk Biosciences raised?

Moonwalk Biosciences has raised ~$127M in total funding (As of Sep 8, 2026, BioSpace).

Who are Moonwalk Biosciences's investors?

Moonwalk Biosciences's investors include Alpha Wave Global, ARCH Venture Partners, Eli Lilly and Company, Future Ventures, Gaorong Ventures, and 1 more (As of Sep 8, 2026).

Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction